Skip to main content
Log in

Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome)

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Siepmann M, Muck-Weymann M, Joraschky P, Kirch W (2001) The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology 157:202–207

    CAS  PubMed  Google Scholar 

  2. Appelbaum PS, Kapoor W (1983) Imipramine-induced vasospasm: a case report. Am J Psychiatry 140:913–915

    CAS  PubMed  Google Scholar 

  3. Anderson RP, Morris BAP (1988) Acrocyanosis due to imipramine. Arch Dis Child 63:204–205

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the U.K. Medicines Control Agency for forwarding the original case details.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I. Ralph Edwards.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clark, D.W.J., Correa-Nunes, AM. & Edwards, I.R. Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome). Eur J Clin Pharmacol 59, 261–262 (2003). https://doi.org/10.1007/s00228-003-0611-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-003-0611-5

Keywords

Navigation